Charges for research and development asset acquisitions
5,271
8,540
0
0
Deferred income taxes
-544
-315
-825
-212
Share-based compensation
298
185
205
204
Other
81
-20
-118
51
Accounts receivable
-
-
1,090
-
Inventories
-
-
1,180
-
Trade accounts payable
-
-
110
-
Accrued and other current liabilities
-
-
-1,841
-
Income taxes payable
-
-
137
-
Noncurrent liabilities
-
-
195
-
Increase Decrease In Other Operating Capital Net
-
-
3,307
-
Net changes in assets and liabilities
-423
-3,044
-
-1,314
Net cash provided by operating activities
5,370
3,918
2,857
7,822
Capital expenditures
893
991
1,033
987
Purchases of securities and other investments
148
374
0
0
Proceeds from sales of securities and other investments
1,303
0
46
575
Proceeds from sale of seagen inc. common stock
-
-
0
-
Acquisition of cidara therapeutics, inc., net of cash acquired
0
8,779
10,042
0
Acquisition of terns pharmaceuticals, inc., net of cash acquired
5,842
-
0
-
Acquisition of elanco animal health incorporated aqua business
-
-
0
0
Acquisition of harpoon therapeutics, inc., net of cash acquired
-
-
0
0
Acquisition of mk-1045 from curon pharmaceutical
-
-
0
0
Acquisition of prometheus biosciences, inc., net of cash acquired
-
-
0
-
Acquisition of imago biosciences inc., net of cash acquired
-
-
0
-
Other
22
66
172
-129
Net cash used in investing activities
-5,602
-10,210
-11,201
-283
Proceeds from term loan
6,000
-
-
-
Net change in short-term borrowings
-
998
-
15
Payments on term loan
6,000
-
-
-
Proceeds from issuance of debt
5,956
-
7,918
5,962
Payments on debt
5
1,140
2
1
Dividends paid to stockholders
2,144
2,105
2,018
2,031
Purchases of treasury stock
757
874
1,252
1,323
Proceeds from exercise of stock options
43
157
47
14
Other
-270
-80
121
2
Net cash used in financing activities
1,762
-2,981
4,751
2,638
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-37
-19
23
10
Net decrease in cash, cash equivalents and restricted cash
1,493
-9,292
-3,570
10,187
Restricted cash
125
125
76
76
Cash, cash equivalents and restricted cash at beginning of year (includes restricted cash of 125 and 76 at january 1, 2026 and 2025, respectively, included in other current assets)
5,398
14,690
8,732
8,732
Cash, cash equivalents and restricted cash at end of period (includes restricted cash of 42 and 66 at june30, 2026 and 2025, respectively, included in other current assets)
6,891
5,398
14,690
18,260
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.